Although TKIs improve outcomes, they are still associated with toxicities common with cancer therapies, such as fatigue.<div><a href="http://www.renalandurologynews.com/renal-cell-carcinoma-fatigue-associated-sorafenib-sunitinib/article/734393/" target="_blank">Original link</a></div>